{"items": "74", "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish", "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.", "feed": [{"title": "Black Diamond Therapeutics to Participate in Upcoming Investor Conferences", "url": "https://www.globenewswire.com/news-release/2024/11/01/2973318/0/en/Black-Diamond-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html", "time_published": "20241101T120000", "authors": ["Inc", "Black Diamond Therapeutics"], "summary": "CAMBRIDGE, Mass., Nov. 01, 2024 ( GLOBE NEWSWIRE ) -- Black Diamond Therapeutics, Inc. ( Nasdaq: BDTX ) , a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/b8da4d92-789b-4f0a-a1e2-2739af370155", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.054412, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.636698", "ticker_sentiment_score": "-0.186002", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug - Black Diamond Therapeutic  ( NASDAQ:BDTX ) ", "url": "https://www.benzinga.com/general/biotech/24/09/40984991/black-diamond-therapeutics-lead-drug-candidate-shows-initial-anti-tumor-activity-in-certain-type-", "time_published": "20240923T154340", "authors": ["Vandana Singh"], "summary": "Monday, Black Diamond Therapeutics, Inc. BDTX reported initial Phase 2 data of BDTX-1535. The data demonstrated encouraging clinical responses and durability of BDTX-1535 in patients with relapsed/refractory epidermal growth factor receptor ( EGFR ) -mutant ( EGFRm ) non-small cell lung cancer ( ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/23/BDTX.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.057027, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.209365", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDTX", "relevance_score": "0.647216", "ticker_sentiment_score": "0.0552", "ticker_sentiment_label": "Neutral"}]}, {"title": "Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations", "url": "https://www.globenewswire.com/news-release/2024/09/23/2951227/0/en/Black-Diamond-Therapeutics-Announces-Initial-Phase-2-Data-Demonstrating-Robust-Anti-tumor-Activity-of-BDTX-1535-in-Patients-with-Recurrent-EGFRm-NSCLC-who-Present-with-a-Broad-Spec.html", "time_published": "20240923T110000", "authors": ["Inc", "Black Diamond Therapeutics"], "summary": "BDTX-1535 dose of 200 mg daily selected for pivotal development. favorable tolerability profile and no new safety signals observed ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/b8da4d92-789b-4f0a-a1e2-2739af370155", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.026413, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.632296", "ticker_sentiment_score": "0.025619", "ticker_sentiment_label": "Neutral"}]}, {"title": "Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC - Black Diamond Therapeutic  ( NASDAQ:BDTX ) ", "url": "https://www.benzinga.com/pressreleases/24/09/g40971257/black-diamond-therapeutics-to-host-webcast-presentation-of-initial-phase-2-bdtx-1535-data-in-patie", "time_published": "20240922T140000", "authors": ["Globe Newswire"], "summary": "Webcast to be held Monday, September 23, at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 22, 2024 ( GLOBE NEWSWIRE ) -- Black Diamond Therapeutics, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.08571, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.775204", "ticker_sentiment_score": "-0.153469", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC", "url": "https://www.globenewswire.com/news-release/2024/09/22/2950985/0/en/Black-Diamond-Therapeutics-to-Host-Webcast-Presentation-of-Initial-Phase-2-BDTX-1535-Data-in-Patients-With-Recurrent-EGFRm-NSCLC.html", "time_published": "20240922T140000", "authors": ["Black Diamond Therapeutics", "Inc"], "summary": "Webcast to be held Monday, September 23, at 8:00 a.m. ET ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/b8da4d92-789b-4f0a-a1e2-2739af370155", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.023801, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.766141", "ticker_sentiment_score": "-0.164519", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology  ( ESMO )  Congress 2024", "url": "https://www.globenewswire.com/news-release/2024/09/14/2946236/0/en/Black-Diamond-Therapeutics-Presents-Real-World-Treatment-Practices-and-Patient-Outcomes-in-Newly-Diagnosed-NSCLC-Patients-with-Non-Classical-Mutations-at-the-European-Society-for-M.html", "time_published": "20240914T073000", "authors": ["Inc", "Black Diamond Therapeutics"], "summary": "Treatment data were analyzed from 3,276 cases of patients with newly diagnosed EGFR mutant NSCLC from Guardant Health ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/b8da4d92-789b-4f0a-a1e2-2739af370155", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": -0.02858, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.456637", "ticker_sentiment_score": "-0.03634", "ticker_sentiment_label": "Neutral"}, {"ticker": "GH", "relevance_score": "0.087985", "ticker_sentiment_score": "0.020567", "ticker_sentiment_label": "Neutral"}]}, {"title": "Looking Into Black Diamond Therapeutic's Recent Short Interest - Black Diamond Therapeutic  ( NASDAQ:BDTX ) ", "url": "https://www.benzinga.com/insights/short-sellers/24/08/40507165/looking-into-black-diamond-therapeutics-recent-short-interest", "time_published": "20240822T131516", "authors": ["Benzinga Insights"], "summary": "Black Diamond Therapeutic's BDTX short percent of float has fallen 6.83% since its last report. The company recently reported that it has 4.44 million shares sold short, which is 13.23% of all regular shares that are available for trading.", "banner_image": "https://www.benzinga.com/files/images/story/2024/1724332513_0.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.27795, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.30569", "ticker_sentiment_score": "0.276384", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update", "url": "https://www.globenewswire.com/news-release/2024/08/13/2928986/0/en/Gyre-Therapeutics-Reports-Second-Quarter-2024-and-Year-To-Date-Financial-Results-and-Provides-Business-Update.html", "time_published": "20240813T100000", "authors": ["Gyre Therapeutics", "Inc."], "summary": "Received NMPA approval of avatrombopag maleate tablets for the treatment of CLD-associated thrombocytopenia, expanding rare disease product lines Received IND approval from NMPA to evaluate F230 for the treatment of pulmonary arterial hypertension U.S.", "banner_image": "https://ml.globenewswire.com/Resource/Download/24951768-57e9-4d7a-b969-f00258b17136", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.161647"}, {"topic": "Economy - Macro", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.121721, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GYRE", "relevance_score": "0.147818", "ticker_sentiment_score": "0.072546", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDTX", "relevance_score": "0.013515", "ticker_sentiment_score": "0.045754", "ticker_sentiment_label": "Neutral"}, {"ticker": "CURN", "relevance_score": "0.027026", "ticker_sentiment_score": "0.047797", "ticker_sentiment_label": "Neutral"}]}, {"title": "Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology  ( ASCO )  Annual Meeting", "url": "https://www.globenewswire.com/news-release/2024/06/01/2891821/0/en/Black-Diamond-Therapeutics-Presents-Promising-BDTX-1535-Clinical-Data-in-Patients-with-Recurrent-Glioblastoma-at-2024-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html", "time_published": "20240601T140000", "authors": ["Black Diamond Therapeutics", "Inc"], "summary": "Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/b8da4d92-789b-4f0a-a1e2-2739af370155", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.024078, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.752006", "ticker_sentiment_score": "0.031695", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.057559", "ticker_sentiment_score": "0.001001", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should You Buy Black Diamond Therapeutics  ( BDTX )  Ahead of Earnings?", "url": "https://www.zacks.com/stock/news/2271998/should-you-buy-black-diamond-therapeutics-bdtx-ahead-of-earnings", "time_published": "20240510T124600", "authors": ["Zacks Equity Research"], "summary": "Black Diamond Therapeutics (BDTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99237"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.418488, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.87799", "ticker_sentiment_score": "0.515953", "ticker_sentiment_label": "Bullish"}, {"ticker": "BDIMF", "relevance_score": "0.560594", "ticker_sentiment_score": "0.567766", "ticker_sentiment_label": "Bullish"}]}, {"title": "Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update", "url": "https://www.globenewswire.com/news-release/2024/05/09/2878644/0/en/Black-Diamond-Therapeutics-Reports-First-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html", "time_published": "20240509T113000", "authors": ["Inc", "Black Diamond Therapeutics"], "summary": "CAMBRIDGE, MA, May 09, 2024 ( GLOBE NEWSWIRE ) -- Black Diamond Therapeutics, Inc. ( Nasdaq: BDTX ) , a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the first quarter ended ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/b8da4d92-789b-4f0a-a1e2-2739af370155", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.839681"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}], "overall_sentiment_score": -0.009444, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.641573", "ticker_sentiment_score": "-0.014554", "ticker_sentiment_label": "Neutral"}, {"ticker": "GH", "relevance_score": "0.030524", "ticker_sentiment_score": "-0.00839", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.240489", "ticker_sentiment_score": "-0.027315", "ticker_sentiment_label": "Neutral"}]}, {"title": "CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors - Cargo Therapeutics  ( NASDAQ:CRGX ) ", "url": "https://www.benzinga.com/pressreleases/24/04/g38258186/cargo-therapeutics-names-kapil-dhingra-m-b-b-s-to-board-of-directors", "time_published": "20240415T200500", "authors": ["Globe Newswire"], "summary": "SAN MATEO, Calif., April 15, 2024 ( GLOBE NEWSWIRE ) -- CARGO Therapeutics, Inc. CRGX, a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced it has appointed Kapil Dhingra, M.B.B.S., to the Company's ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.795202"}], "overall_sentiment_score": 0.109403, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AUTL", "relevance_score": "0.033846", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.033846", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRGNF", "relevance_score": "0.033846", "ticker_sentiment_score": "0.01176", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDTX", "relevance_score": "0.033846", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.033846", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LVTX", "relevance_score": "0.033846", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRGX", "relevance_score": "0.233556", "ticker_sentiment_score": "0.123569", "ticker_sentiment_label": "Neutral"}]}, {"title": "Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting", "url": "https://www.globenewswire.com/news-release/2024/04/07/2858854/0/en/Black-Diamond-Therapeutics-Presents-Novel-Real-World-Evidence-of-the-Evolving-EGFR-Mutation-Landscape-in-NSCLC-and-the-Opportunity-for-BDTX-1535-in-an-Oral-Presentation-at-the-2024.html", "time_published": "20240407T220000", "authors": ["Black Diamond Therapeutics", "Inc"], "summary": "Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/b8da4d92-789b-4f0a-a1e2-2739af370155", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.161647"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": -0.035916, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.601612", "ticker_sentiment_score": "-0.095481", "ticker_sentiment_label": "Neutral"}, {"ticker": "GH", "relevance_score": "0.032078", "ticker_sentiment_score": "-0.00947", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.096027", "ticker_sentiment_score": "0.028735", "ticker_sentiment_label": "Neutral"}]}, {"title": "Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update", "url": "https://www.globenewswire.com/news-release/2024/03/12/2844449/0/en/Black-Diamond-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Corporate-Update.html", "time_published": "20240312T120000", "authors": ["Black Diamond Therapeutics", "Inc"], "summary": "CAMBRIDGE, Mass., March 12, 2024 ( GLOBE NEWSWIRE ) -- Black Diamond Therapeutics, Inc. ( Nasdaq: BDTX ) , a clinical-stage oncology company focused on the development of MasterKey therapies to treat patients with genetically defined tumors, today reported financial results for the fourth ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/b8da4d92-789b-4f0a-a1e2-2739af370155", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.839681"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.002376, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.689975", "ticker_sentiment_score": "0.003783", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.247278", "ticker_sentiment_score": "-0.005653", "ticker_sentiment_label": "Neutral"}]}, {"title": "Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones - Black Diamond Therapeutic  ( NASDAQ:BDTX ) ", "url": "https://www.benzinga.com/pressreleases/24/01/g36488013/black-diamond-therapeutics-announces-corporate-update-and-expected-2024-milestones", "time_published": "20240104T130000", "authors": ["Globe Newswire"], "summary": "FDA feedback on BDTX-1535 enables initiation of Phase 2 cohort in first-line treatment of non-classical EGFR mutant NSCLC Fast Track Designation granted for BDTX-1535 as second-line treatment for EGFR mutant/C797S NSCLC BDTX-1535 Phase 2 results for 2L/3L patients with EGFR mutant NSCLC expected ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.016672, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.851436", "ticker_sentiment_score": "0.028994", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.190267", "ticker_sentiment_score": "0.115948", "ticker_sentiment_label": "Neutral"}]}, {"title": "Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM", "url": "https://www.globenewswire.com/news-release/2023/12/13/2795402/0/en/Black-Diamond-Therapeutics-Announces-Topline-Results-from-Phase-1-Dose-Escalation-Trial-of-BDTX-1535-in-Patients-with-Recurrent-GBM.html", "time_published": "20231213T120000", "authors": ["Black Diamond Therapeutics", "Inc"], "summary": "Initial results show promising clinical activity in heavily pretreated patients ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/b8da4d92-789b-4f0a-a1e2-2739af370155", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.057491, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.614564", "ticker_sentiment_score": "0.046798", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.090134", "ticker_sentiment_score": "0.061829", "ticker_sentiment_label": "Neutral"}]}, {"title": "Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update", "url": "https://www.globenewswire.com/news-release/2023/11/06/2774003/0/en/Black-Diamond-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html", "time_published": "20231106T124500", "authors": ["Black Diamond Therapeutics", "Inc"], "summary": "CAMBRIDGE, Mass. and NEW YORK, Nov. 06, 2023 ( GLOBE NEWSWIRE ) -- Black Diamond Therapeutics, Inc. ( Nasdaq: BDTX ) , a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today reported ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/b8da4d92-789b-4f0a-a1e2-2739af370155", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.839681"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.047734, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.641083", "ticker_sentiment_score": "0.073201", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.240251", "ticker_sentiment_score": "0.042602", "ticker_sentiment_label": "Neutral"}]}, {"title": "Black Diamond Therapeutics And 2 Other Stocks Under $3 Insiders Are Buying - Bespoke Extracts  ( OTC:BSPK ) , Black Diamond Therapeutic  ( NASDAQ:BDTX ) ", "url": "https://www.benzinga.com/trading-ideas/long-ideas/23/10/35349089/black-diamond-therapeutics-and-2-other-stocks-under-3-insiders-are-buying", "time_published": "20231020T125510", "authors": ["Lisa Levin"], "summary": "The Dow Jones closed lower by around 250 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/20/image17.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.161647"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.142136, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.60415", "ticker_sentiment_score": "0.38141", "ticker_sentiment_label": "Bullish"}, {"ticker": "BDIMF", "relevance_score": "0.428632", "ticker_sentiment_score": "0.31448", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535", "url": "https://www.globenewswire.com/news-release/2023/10/14/2760230/0/en/Black-Diamond-Therapeutics-Presents-Dose-Escalation-Data-Demonstrating-Durable-Responses-in-Patients-with-NSCLC-from-Phase-1-Trial-of-BDTX-1535.html", "time_published": "20231014T163000", "authors": ["Inc", "Black Diamond Therapeutics"], "summary": "Initial results from BDTX-1535 dose escalation show durable activity in patients with NSCLC across heterogeneous EGFR mutation subtypes ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/b8da4d92-789b-4f0a-a1e2-2739af370155", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.266143"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": -0.009683, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.682689", "ticker_sentiment_score": "-0.011433", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.116914", "ticker_sentiment_score": "0.028796", "ticker_sentiment_label": "Neutral"}]}, {"title": "Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Black Diamond Therapeutic  ( NASDAQ:BDTX ) ", "url": "https://www.benzinga.com/pressreleases/23/10/g35093215/black-diamond-therapeutics-to-present-preclinical-and-clinical-data-at-the-aacr-nci-eortc-internat", "time_published": "20231004T161400", "authors": ["Globe Newswire"], "summary": "CAMBRIDGE, Mass. and NEW YORK, Oct. 04, 2023 ( GLOBE NEWSWIRE ) -- Black Diamond Therapeutics, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.033249, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.759278", "ticker_sentiment_score": "-0.063096", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.32478", "ticker_sentiment_score": "0.04949", "ticker_sentiment_label": "Neutral"}]}, {"title": "Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics", "url": "https://www.globenewswire.com/news-release/2023/10/04/2754838/0/en/Black-Diamond-Therapeutics-to-Present-Preclinical-and-Clinical-Data-at-the-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics.html", "time_published": "20231004T161400", "authors": ["Inc", "Black Diamond Therapeutics"], "summary": "CAMBRIDGE, Mass. and NEW YORK, Oct. 04, 2023 ( GLOBE NEWSWIRE ) -- Black Diamond Therapeutics, Inc. ( Nasdaq: BDTX ) , a clinical-stage precision oncology company developing therapies that target families of oncogenic mutations in patients with genetically defined cancers, today announced ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/b8da4d92-789b-4f0a-a1e2-2739af370155", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": -0.028717, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.677342", "ticker_sentiment_score": "-0.026449", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.1568", "ticker_sentiment_score": "0.117106", "ticker_sentiment_label": "Neutral"}]}, {"title": "Black Diamond Therapeutics Announces CEO Transition - Black Diamond Therapeutic  ( NASDAQ:BDTX ) , G1 Therapeutics  ( NASDAQ:GTHX ) ", "url": "https://www.benzinga.com/pressreleases/23/09/g34682997/black-diamond-therapeutics-announces-ceo-transition", "time_published": "20230918T110000", "authors": ["Globe Newswire"], "summary": "Current Chairman of the Board and industry veteran Mark Velleca appointed CEO CAMBRIDGE, Mass. and NEW YORK, Sept. 18, 2023 ( GLOBE NEWSWIRE ) -- Black Diamond Therapeutics, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.227457, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.342487", "ticker_sentiment_score": "0.35462", "ticker_sentiment_label": "Bullish"}, {"ticker": "BDIMF", "relevance_score": "0.445569", "ticker_sentiment_score": "0.405311", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.058903", "ticker_sentiment_score": "-0.061986", "ticker_sentiment_label": "Neutral"}, {"ticker": "GTHX", "relevance_score": "0.117486", "ticker_sentiment_score": "0.120169", "ticker_sentiment_label": "Neutral"}]}, {"title": "Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer", "url": "https://www.globenewswire.com/news-release/2023/09/11/2740720/0/en/Black-Diamond-Therapeutics-Announces-First-Patients-Dosed-in-Phase-1-Clinical-Trial-Expansion-Cohorts-Evaluating-BDTX-1535-in-Patients-with-Intrinsic-Driver-and-Acquired-Resistance.html", "time_published": "20230911T120000", "authors": ["Inc", "Black Diamond Therapeutics"], "summary": "Company to present BDTX-1535 dose escalation data in NSCLC at the AACR-NCI-EORTC Conference in October ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/b8da4d92-789b-4f0a-a1e2-2739af370155", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.316726"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.016785, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.662301", "ticker_sentiment_score": "0.026139", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.126951", "ticker_sentiment_score": "0.042105", "ticker_sentiment_label": "Neutral"}]}, {"title": "SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer", "url": "https://www.globenewswire.com/news-release/2023/09/11/2740616/0/en/SpringWorks-Therapeutics-Appoints-Dr-Tai-An-Lin-as-Chief-Scientific-Officer.html", "time_published": "20230911T103000", "authors": ["Inc.", "SpringWorks Therapeutics"], "summary": "STAMFORD, Conn., Sept. 11, 2023 ( GLOBE NEWSWIRE ) -- SpringWorks Therapeutics, Inc. ( Nasdaq: SWTX ) , a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the appointment of Tai-An Lin, ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/03870757-75d0-4869-a7a0-98e8d7ffbc21", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.149745, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.038717", "ticker_sentiment_score": "0.010654", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.077343", "ticker_sentiment_score": "0.011182", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.038717", "ticker_sentiment_score": "0.010654", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWTX", "relevance_score": "0.077343", "ticker_sentiment_score": "-0.055998", "ticker_sentiment_label": "Neutral"}]}, {"title": "SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer - SpringWorks Therapeutics  ( NASDAQ:SWTX ) ", "url": "https://www.benzinga.com/pressreleases/23/09/g34432690/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer", "time_published": "20230911T103000", "authors": ["Globe Newswire"], "summary": "STAMFORD, Conn., Sept. 11, 2023 ( GLOBE NEWSWIRE ) -- SpringWorks Therapeutics, Inc. SWTX, a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the appointment of Tai-An Lin, Ph.D., as its Chief ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.140244, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.037098", "ticker_sentiment_score": "0.010592", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.074115", "ticker_sentiment_score": "0.011129", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.037098", "ticker_sentiment_score": "0.010592", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWTX", "relevance_score": "0.074115", "ticker_sentiment_score": "-0.054695", "ticker_sentiment_label": "Neutral"}]}, {"title": "Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update", "url": "https://www.globenewswire.com/news-release/2023/08/11/2723463/0/en/Black-Diamond-Therapeutics-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html", "time_published": "20230811T113000", "authors": ["Black Diamond Therapeutics", "Inc"], "summary": "CAMBRIDGE, Mass. and NEW YORK, Aug. 11, 2023 ( GLOBE NEWSWIRE ) -- Black Diamond Therapeutics, Inc. ( Nasdaq: BDTX ) , a clinical-stage precision oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/b8da4d92-789b-4f0a-a1e2-2739af370155", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.890401"}, {"topic": "Financial Markets", "relevance_score": "0.990893"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.019149, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.606892", "ticker_sentiment_score": "0.028569", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.380012", "ticker_sentiment_score": "0.026598", "ticker_sentiment_label": "Neutral"}]}, {"title": "$4.7M Bet On Black Diamond Therapeutics? Check Out These 3 Stocks Insiders Are Buying - Black Diamond Therapeutic  ( NASDAQ:BDTX ) , Domo  ( NASDAQ:DOMO ) ", "url": "https://www.benzinga.com/trading-ideas/long-ideas/23/07/33165058/4-7m-bet-on-black-diamond-therapeutics-check-out-these-3-stocks-insiders-are-buying", "time_published": "20230710T125158", "authors": ["Lisa Levin"], "summary": "Although US stocks closed lower on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/10/black_diamond_therapeutics_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.309226, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.512596", "ticker_sentiment_score": "0.462968", "ticker_sentiment_label": "Bullish"}, {"ticker": "BDIMF", "relevance_score": "0.421485", "ticker_sentiment_score": "0.414501", "ticker_sentiment_label": "Bullish"}, {"ticker": "DOMO", "relevance_score": "0.512596", "ticker_sentiment_score": "0.344619", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SCWX", "relevance_score": "0.512596", "ticker_sentiment_score": "0.390379", "ticker_sentiment_label": "Bullish"}]}, {"title": "Nanobiotix, NanoString Technologies And Other Big Stocks Moving Higher In Monday's Pre-Market Session - Black Diamond Therapeutic  ( NASDAQ:BDTX ) , Gorilla Tech Gr  ( NASDAQ:GRRR ) ", "url": "https://www.benzinga.com/news/23/07/33162844/nanobiotix-nanostring-technologies-and-other-big-stocks-moving-higher-in-mondays-pre-market-session", "time_published": "20230710T104008", "authors": ["Lisa Levin"], "summary": "Nanobiotix S.A. NBTX shares jumped 59.3% to $8.02 in pre-market trading after the company entered into a license agreement with Janssen Pharmaceutical for global co-development and commercialization of NBTXR3. Black Diamond Therapeutics, Inc. BDTX shares gained 15.2% to $5.08 in pre-market ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/10/image27.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.37431, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "GSM", "relevance_score": "0.423843", "ticker_sentiment_score": "-0.049995", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVX", "relevance_score": "0.290607", "ticker_sentiment_score": "-0.353781", "ticker_sentiment_label": "Bearish"}, {"ticker": "BDIMF", "relevance_score": "0.290607", "ticker_sentiment_score": "0.57928", "ticker_sentiment_label": "Bullish"}, {"ticker": "LAW", "relevance_score": "0.290607", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDTX", "relevance_score": "0.423843", "ticker_sentiment_score": "0.703238", "ticker_sentiment_label": "Bullish"}, {"ticker": "GRRR", "relevance_score": "0.423843", "ticker_sentiment_score": "0.581741", "ticker_sentiment_label": "Bullish"}, {"ticker": "RXRX", "relevance_score": "0.290607", "ticker_sentiment_score": "0.395089", "ticker_sentiment_label": "Bullish"}, {"ticker": "PSNY", "relevance_score": "0.290607", "ticker_sentiment_score": "0.537139", "ticker_sentiment_label": "Bullish"}, {"ticker": "NBTX", "relevance_score": "0.290607", "ticker_sentiment_score": "0.340393", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NSTG", "relevance_score": "0.290607", "ticker_sentiment_score": "0.340393", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "$1M Bet On Children's Place? Check Out These 3 Stocks Insiders Are Buying - Black Diamond Therapeutic  ( NASDAQ:BDTX ) , Nuvectis Pharma  ( NASDAQ:NVCT ) ", "url": "https://www.benzinga.com/trading-ideas/long-ideas/23/07/33145641/1m-bet-on-childrens-place-check-out-these-3-stocks-insiders-are-buying", "time_published": "20230707T111925", "authors": ["Lisa Levin"], "summary": "Although US stocks closed lower on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/07/childrens_place_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.298252, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.518708", "ticker_sentiment_score": "0.460682", "ticker_sentiment_label": "Bullish"}, {"ticker": "BDIMF", "relevance_score": "0.426824", "ticker_sentiment_score": "0.412929", "ticker_sentiment_label": "Bullish"}, {"ticker": "PLCE", "relevance_score": "0.518708", "ticker_sentiment_score": "0.297749", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVCT", "relevance_score": "0.518708", "ticker_sentiment_score": "0.366461", "ticker_sentiment_label": "Bullish"}]}, {"title": "$5M Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying - Black Diamond Therapeutic  ( NASDAQ:BDTX ) , Healthcare Services Group  ( NASDAQ:HCSG ) ", "url": "https://www.benzinga.com/trading-ideas/long-ideas/23/07/33114903/5m-bet-on-this-biotechnology-stock-check-out-these-3-stocks-insiders-are-buying", "time_published": "20230705T125302", "authors": ["Lisa Levin"], "summary": "Although US stocks closed slightly higher on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/05/image16.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.322297, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.496915", "ticker_sentiment_score": "0.368914", "ticker_sentiment_label": "Bullish"}, {"ticker": "BDIMF", "relevance_score": "0.407844", "ticker_sentiment_score": "0.326819", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HCSG", "relevance_score": "0.496915", "ticker_sentiment_score": "0.223138", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Genuine Monotherapy Approach In EGFRm NSCLC: Analyst Upgrades Switches To Buy On Black Diamond Therapeutics - Black Diamond Therapeutic  ( NASDAQ:BDTX ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/06/33082668/genuine-monotherapy-approach-in-egfrm-nsclc-analyst-upgrades-switches-to-buy-on-bla", "time_published": "20230630T184730", "authors": ["Vandana Singh"], "summary": "Tuesday, Black Diamond Therapeutics Inc BDTX announced initial clinical data from the dose escalation portion of Phase 1 clinical study of BDTX-1535 for non-small cell lung cancer ( NSCLC ) and glioblastoma multiforme ( GBM ) .", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/06/30/bdtx.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.016687, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.817578", "ticker_sentiment_score": "-0.117491", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.132368", "ticker_sentiment_score": "-0.143532", "ticker_sentiment_label": "Neutral"}]}, {"title": "$1.5M Bet On ONEOK? Check Out These 3 Stocks Insiders Are Buying - Black Diamond Therapeutic  ( NASDAQ:BDTX ) , Landmark Bancorp  ( NASDAQ:LARK ) ", "url": "https://www.benzinga.com/trading-ideas/long-ideas/23/06/33076856/1-5m-bet-on-oneok-check-out-these-3-stocks-insiders-are-buying", "time_published": "20230630T122541", "authors": ["Lisa Levin"], "summary": "Although US stocks closed mostly higher on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/06/30/image19.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.307374, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "OKE", "relevance_score": "0.412861", "ticker_sentiment_score": "0.513585", "ticker_sentiment_label": "Bullish"}, {"ticker": "BDTX", "relevance_score": "0.58463", "ticker_sentiment_score": "0.013991", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.412861", "ticker_sentiment_score": "0.011284", "ticker_sentiment_label": "Neutral"}, {"ticker": "RPRX", "relevance_score": "0.107978", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LARK", "relevance_score": "0.502693", "ticker_sentiment_score": "0.509741", "ticker_sentiment_label": "Bullish"}]}, {"title": "Black Diamond Therapeutics Announces Pricing of Public Offering of Common Stock", "url": "https://www.globenewswire.com/news-release/2023/06/30/2697495/0/en/Black-Diamond-Therapeutics-Announces-Pricing-of-Public-Offering-of-Common-Stock.html", "time_published": "20230630T005700", "authors": ["Inc", "Black Diamond Therapeutics"], "summary": "CAMBRIDGE, Mass and NEW YORK, June 29, 2023 ( GLOBE NEWSWIRE ) -- Black Diamond Therapeutics, Inc. ( Nasdaq: BDTX ) , a clinical-stage precision oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/b8da4d92-789b-4f0a-a1e2-2739af370155", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.451494"}, {"topic": "Financial Markets", "relevance_score": "0.818451"}], "overall_sentiment_score": 0.08324, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.276491", "ticker_sentiment_score": "0.142192", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.47574", "ticker_sentiment_score": "0.089705", "ticker_sentiment_label": "Neutral"}]}, {"title": "Black Diamond Therapeutics Announces Pricing of Public Offering of Common Stock - Black Diamond Therapeutic  ( NASDAQ:BDTX ) ", "url": "https://www.benzinga.com/pressreleases/23/06/g33070501/black-diamond-therapeutics-announces-pricing-of-public-offering-of-common-stock", "time_published": "20230630T005700", "authors": ["Globe Newswire"], "summary": "CAMBRIDGE, Mass and NEW YORK, June 29, 2023 ( GLOBE NEWSWIRE ) -- Black Diamond Therapeutics, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.451494"}, {"topic": "Financial Markets", "relevance_score": "0.891286"}], "overall_sentiment_score": 0.071353, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.267413", "ticker_sentiment_score": "0.138431", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.461468", "ticker_sentiment_score": "0.087948", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Shares of Black Diamond Therapeutics Skyrocketed This Week", "url": "https://www.fool.com/investing/2023/06/29/why-shares-of-black-diamond-therapeutics-skyrocket/", "time_published": "20230629T214800", "authors": ["Jim Halley"], "summary": "The company announced positive early-trial news for non-small cell lung cancer.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F737525%2Fprofessional-stock-trader-broker-analyze-stock-chart-invest-retire-getty.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.0, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.68039", "ticker_sentiment_score": "-0.057112", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.113062", "ticker_sentiment_score": "0.014753", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.330286", "ticker_sentiment_score": "-0.03644", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why CorMedix Are Trading Lower By 22%; Here Are 20 Stocks Moving Premarket - Akso Health Group  ( NASDAQ:AHG ) , BlackBerry  ( NYSE:BB ) ", "url": "https://www.benzinga.com/news/23/06/33057313/why-cormedix-are-trading-lower-by-22-here-are-20-stocks-moving-premarket", "time_published": "20230629T121831", "authors": ["Lisa Levin"], "summary": "Eco Wave Power Global AB WAVE shares surged 123% to $3.48 in pre-market trading after dropping over 8% on Wednesday. Kintara Therapeutics, Inc. KTRA shares gained 33.1% to $3.98 in pre-market trading after the company secured $2.0 million National Institutes of Health SBIR grant to support ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/06/29/image31.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.144138, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AHG", "relevance_score": "0.142565", "ticker_sentiment_score": "0.324567", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BB", "relevance_score": "0.142565", "ticker_sentiment_score": "0.231115", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CNTG", "relevance_score": "0.212425", "ticker_sentiment_score": "-0.186022", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BDIMF", "relevance_score": "0.07157", "ticker_sentiment_score": "0.091516", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZIVO", "relevance_score": "0.142565", "ticker_sentiment_score": "-0.217463", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "IMBIL", "relevance_score": "0.07157", "ticker_sentiment_score": "-0.189455", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JAGX", "relevance_score": "0.212425", "ticker_sentiment_score": "-0.044192", "ticker_sentiment_label": "Neutral"}, {"ticker": "WAVE", "relevance_score": "0.142565", "ticker_sentiment_score": "0.157955", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KSCP", "relevance_score": "0.142565", "ticker_sentiment_score": "-0.126956", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDTX", "relevance_score": "0.142565", "ticker_sentiment_score": "0.112088", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRMD", "relevance_score": "0.142565", "ticker_sentiment_score": "-0.136873", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHPW", "relevance_score": "0.142565", "ticker_sentiment_score": "0.264427", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KTRA", "relevance_score": "0.142565", "ticker_sentiment_score": "0.436428", "ticker_sentiment_label": "Bullish"}, {"ticker": "NOVN", "relevance_score": "0.142565", "ticker_sentiment_score": "-0.016295", "ticker_sentiment_label": "Neutral"}, {"ticker": "SFR", "relevance_score": "0.142565", "ticker_sentiment_score": "-0.016295", "ticker_sentiment_label": "Neutral"}, {"ticker": "DUO", "relevance_score": "0.212425", "ticker_sentiment_score": "0.135987", "ticker_sentiment_label": "Neutral"}, {"ticker": "NERV", "relevance_score": "0.212425", "ticker_sentiment_score": "0.060144", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRGA", "relevance_score": "0.212425", "ticker_sentiment_score": "0.394783", "ticker_sentiment_label": "Bullish"}]}, {"title": "Black Diamond Therapeutics Announces Proposed Public Offering of Common Stock - Black Diamond Therapeutic  ( NASDAQ:BDTX ) ", "url": "https://www.benzinga.com/pressreleases/23/06/g33050417/black-diamond-therapeutics-announces-proposed-public-offering-of-common-stock", "time_published": "20230628T202352", "authors": ["Globe Newswire"], "summary": "CAMBRIDGE, Mass. and NEW YORK, June 28, 2023 ( GLOBE NEWSWIRE ) -- Black Diamond Therapeutics, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.451494"}, {"topic": "Financial Markets", "relevance_score": "0.891286"}], "overall_sentiment_score": 0.068828, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.2589", "ticker_sentiment_score": "0.132737", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.402941", "ticker_sentiment_score": "0.077402", "ticker_sentiment_label": "Neutral"}]}, {"title": "Black Diamond Therapeutics Announces Proposed Public Offering of Common Stock", "url": "https://www.globenewswire.com/news-release/2023/06/28/2696620/0/en/Black-Diamond-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock.html", "time_published": "20230628T202300", "authors": ["Black Diamond Therapeutics", "Inc"], "summary": "CAMBRIDGE, Mass. and NEW YORK, June 28, 2023 ( GLOBE NEWSWIRE ) -- Black Diamond Therapeutics, Inc. ( Nasdaq: BDTX ) , a clinical-stage precision oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/b8da4d92-789b-4f0a-a1e2-2739af370155", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.451494"}, {"topic": "Financial Markets", "relevance_score": "0.818451"}], "overall_sentiment_score": 0.078314, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.267413", "ticker_sentiment_score": "0.138217", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.415413", "ticker_sentiment_score": "0.079088", "ticker_sentiment_label": "Neutral"}]}, {"title": "Tesla And Nvidia Lead The Charge As Stocks Surge: Top Trends Of The Day - NVIDIA  ( NASDAQ:NVDA ) , Tesla  ( NASDAQ:TSLA ) , Advanced Micro Devices  ( NASDAQ:AMD ) , Micron Technology  ( NASDAQ:MU ) , Black Diamond Therapeutic  ( NASDAQ:BDTX ) , TD Synnex  ( NYSE:SNX ) , AST SpaceMobile  ( NASDAQ:ASTS ) , Taiwan Semiconductor  ( NYSE:TSM ) ", "url": "https://www.benzinga.com/news/23/06/33036590/tesla-and-nvidia-lead-the-charge-as-stocks-surge-top-trends-of-the-day", "time_published": "20230628T024327", "authors": ["Benzinga Newsbot"], "summary": "U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Tuesday. The Dow traded up 0.73% to 33,959.64 while the Nasdaq rose 1.75% to 13,569.42. The S&P 500 also rose, gaining 1.22% to 4,381.53.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Tesla_stock_9.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": -0.040554, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.2256", "ticker_sentiment_score": "0.036802", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.076115", "ticker_sentiment_score": "-0.103138", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.151539", "ticker_sentiment_score": "-0.062361", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNOW", "relevance_score": "0.076115", "ticker_sentiment_score": "0.10795", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.076115", "ticker_sentiment_score": "-0.103138", "ticker_sentiment_label": "Neutral"}, {"ticker": "MU", "relevance_score": "0.151539", "ticker_sentiment_score": "-0.158495", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BDTX", "relevance_score": "0.151539", "ticker_sentiment_score": "-0.162345", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ASTS", "relevance_score": "0.076115", "ticker_sentiment_score": "-0.152892", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Nasdaq Jumps Over 200 Points; TD Synnex Posts Downbeat Results - Black Diamond Therapeutic  ( NASDAQ:BDTX ) , Adicet Bio  ( NASDAQ:ACET ) ", "url": "https://www.benzinga.com/news/earnings/23/06/33032310/nasdaq-jumps-over-200-points-td-synnex-posts-downbeat-results", "time_published": "20230627T190438", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Tuesday. The Dow traded up 0.73% to 33,959.64 while the NASDAQ rose 1.75% to 13,569.42. The S&P 500, also rose, gaining, 1.22% to 4,381.53. Information technology shares jumped by 2.1% ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/06/27/td_synnex_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.083277, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GIS", "relevance_score": "0.054114", "ticker_sentiment_score": "0.004002", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNTG", "relevance_score": "0.107978", "ticker_sentiment_score": "0.098966", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.054114", "ticker_sentiment_score": "0.012021", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYTA", "relevance_score": "0.107978", "ticker_sentiment_score": "0.130534", "ticker_sentiment_label": "Neutral"}, {"ticker": "TIVC", "relevance_score": "0.107978", "ticker_sentiment_score": "0.371565", "ticker_sentiment_label": "Bullish"}, {"ticker": "BDTX", "relevance_score": "0.161349", "ticker_sentiment_score": "0.017039", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAH", "relevance_score": "0.054114", "ticker_sentiment_score": "0.338996", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNX", "relevance_score": "0.161349", "ticker_sentiment_score": "-0.158675", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "RIDE", "relevance_score": "0.107978", "ticker_sentiment_score": "0.036393", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACET", "relevance_score": "0.161349", "ticker_sentiment_score": "0.273456", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Penny Stocks to Buy? 3 Stocks To Watch Under $5", "url": "https://pennystocks.com/featured/2023/06/27/penny-stocks-to-buy-5-stocks-to-watch-under-5/", "time_published": "20230627T174236", "authors": ["J. Samuel"], "summary": "Today we are diving into the world of penny stocks. This sector has a notorious reputation in the market, and rightfully so - it can be volatile and risky. However, with the right approach, a level head, and disciplined strategies, penny stocks can offer some potential opportunities.", "banner_image": null, "source": "PennyStocks.com", "category_within_source": "n/a", "source_domain": "pennystocks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.938238"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.168577, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.06211", "ticker_sentiment_score": "0.014065", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.031079", "ticker_sentiment_score": "0.013448", "ticker_sentiment_label": "Neutral"}, {"ticker": "SIRI", "relevance_score": "0.123844", "ticker_sentiment_score": "0.037698", "ticker_sentiment_label": "Neutral"}, {"ticker": "QBTS", "relevance_score": "0.06211", "ticker_sentiment_score": "0.165274", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Dow Surges Over 100 Points; Walgreens Lowers Earnings Forecast - Black Diamond Therapeutic  ( NASDAQ:BDTX ) , Adicet Bio  ( NASDAQ:ACET ) ", "url": "https://www.benzinga.com/news/earnings/23/06/33030216/dow-surges-over-100-points-walgreens-lowers-earnings-forecast", "time_published": "20230627T170359", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 100 points on Tuesday. The Dow traded up 0.39% to 33,845.82 while the NASDAQ rose 0.55% to 13,408.91. The S&P 500, also rose, gaining, 0.46% to 4,348.76. Consumer discretionary shares jumped by 1% on Tuesday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/06/27/image48.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.650727"}], "overall_sentiment_score": 0.107123, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CNTG", "relevance_score": "0.110209", "ticker_sentiment_score": "0.099664", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.055236", "ticker_sentiment_score": "0.012029", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYTA", "relevance_score": "0.110209", "ticker_sentiment_score": "0.131576", "ticker_sentiment_label": "Neutral"}, {"ticker": "TIVC", "relevance_score": "0.110209", "ticker_sentiment_score": "0.374055", "ticker_sentiment_label": "Bullish"}, {"ticker": "WBA", "relevance_score": "0.110209", "ticker_sentiment_score": "0.104798", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDTX", "relevance_score": "0.164656", "ticker_sentiment_score": "0.017275", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAH", "relevance_score": "0.055236", "ticker_sentiment_score": "0.339006", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RIDE", "relevance_score": "0.110209", "ticker_sentiment_score": "0.036719", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACET", "relevance_score": "0.164656", "ticker_sentiment_score": "0.276974", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Black Diamond Therapeutics Stock is Shooting Higher Today: Here's Why - Black Diamond Therapeutic  ( NASDAQ:BDTX ) ", "url": "https://www.benzinga.com/general/biotech/23/06/33022988/black-diamond-therapeutics-stock-is-shooting-higher-today-heres-why", "time_published": "20230627T135244", "authors": ["Vandana Singh"], "summary": "Black Diamond Therapeutics Inc BDTX announced initial clinical data from the dose escalation portion of the Phase 1 clinical study of BDTX-1535 for non-small cell lung cancer ( NSCLC ) and glioblastoma multiforme ( GBM ) .", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/06/27/bdtx.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.056886, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.849318", "ticker_sentiment_score": "-0.049131", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.142565", "ticker_sentiment_score": "-0.149273", "ticker_sentiment_label": "Neutral"}]}, {"title": "Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families", "url": "https://www.globenewswire.com/news-release/2023/06/27/2695147/0/en/Black-Diamond-Therapeutics-Announces-Initial-Dose-Escalation-Data-Demonstrating-Anti-Tumor-Activity-of-BDTX-1535-in-Non-Small-Cell-Lung-Cancer-Patients-Across-Multiple-EGFR-Mutatio.html", "time_published": "20230627T110000", "authors": ["Inc", "Black Diamond Therapeutics"], "summary": "CAMBRIDGE, Mass. and NEW YORK, June 27, 2023 ( GLOBE NEWSWIRE ) -- Black Diamond Therapeutics, Inc. ( Nasdaq: BDTX ) , a clinical-stage precision oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/b8da4d92-789b-4f0a-a1e2-2739af370155", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.5855"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.054891, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.556361", "ticker_sentiment_score": "0.07136", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.137334", "ticker_sentiment_score": "0.056883", "ticker_sentiment_label": "Neutral"}]}, {"title": "Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families - Black Diamond Therapeutic  ( NASDAQ:BDTX ) ", "url": "https://www.benzinga.com/pressreleases/23/06/g33019574/black-diamond-therapeutics-announces-initial-dose-escalation-data-demonstrating-anti-tumor-activit", "time_published": "20230627T110000", "authors": ["Globe Newswire"], "summary": "BDTX-1535, an epidermal growth factor receptor ( EGFR ) MasterKey inhibitor, demonstrates clinical proof of activity for MasterKey mutation-targeting approach based on radiographic tumor responses and circulating tumor DNA changes in NSCLC patients with acquired resistance and intrinsic driver ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.5855"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.050109, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.551147", "ticker_sentiment_score": "0.084451", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.135784", "ticker_sentiment_score": "0.06541", "ticker_sentiment_label": "Neutral"}]}, {"title": "Black Diamond Therapeutics Announces Promotion of Melanie Morrison to Chief Development Officer - Black Diamond Therapeutic  ( NASDAQ:BDTX ) ", "url": "https://www.benzinga.com/pressreleases/23/06/g32832558/black-diamond-therapeutics-announces-promotion-of-melanie-morrison-to-chief-development-officer", "time_published": "20230613T120000", "authors": ["Globe Newswire"], "summary": "CAMBRIDGE, Mass. and NEW YORK, June 13, 2023 ( GLOBE NEWSWIRE ) -- Black Diamond Therapeutics, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.109717, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HESG", "relevance_score": "0.116914", "ticker_sentiment_score": "0.023833", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDTX", "relevance_score": "0.443626", "ticker_sentiment_score": "0.106703", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.443626", "ticker_sentiment_score": "0.150169", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.058615", "ticker_sentiment_score": "0.021003", "ticker_sentiment_label": "Neutral"}, {"ticker": "NUVB", "relevance_score": "0.058615", "ticker_sentiment_score": "0.021003", "ticker_sentiment_label": "Neutral"}]}, {"title": "Black Diamond Therapeutics to Present at the Jefferies Healthcare Conference", "url": "https://www.globenewswire.com/news-release/2023/06/02/2681098/0/en/Black-Diamond-Therapeutics-to-Present-at-the-Jefferies-Healthcare-Conference.html", "time_published": "20230602T120000", "authors": ["Inc", "Black Diamond Therapeutics"], "summary": "CAMBRIDGE, Mass. and NEW YORK, June 02, 2023 ( GLOBE NEWSWIRE ) -- Black Diamond Therapeutics, Inc. ( Nasdaq: BDTX ) , a clinical-stage precision oncology medicine company developing MasterKey therapies designed to overcome limitations of existing therapies by targeting families of oncogenic ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/b8da4d92-789b-4f0a-a1e2-2739af370155", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.052483, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.723441", "ticker_sentiment_score": "0.066012", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.465901", "ticker_sentiment_score": "0.052117", "ticker_sentiment_label": "Neutral"}]}, {"title": "Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update", "url": "https://www.globenewswire.com/news-release/2023/05/09/2664295/0/en/Black-Diamond-Therapeutics-Reports-First-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html", "time_published": "20230509T113000", "authors": ["Inc", "Black Diamond Therapeutics"], "summary": "CAMBRIDGE, Mass. and NEW YORK, May 09, 2023 ( GLOBE NEWSWIRE ) -- Black Diamond Therapeutics, Inc. ( Nasdaq: BDTX ) , a clinical-stage precision oncology medicine company developing MasterKey therapies designed to overcome limitations of existing therapies by targeting families of oncogenic ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/b8da4d92-789b-4f0a-a1e2-2739af370155", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.839681"}], "overall_sentiment_score": 0.071272, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.690822", "ticker_sentiment_score": "0.113192", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.410978", "ticker_sentiment_score": "0.111397", "ticker_sentiment_label": "Neutral"}]}, {"title": "Zevra Therapeutics Appoints Biopharma Veteran Wendy Dixon, Ph.D., to Board of Directors", "url": "https://www.globenewswire.com/news-release/2023/03/30/2637531/16626/en/Zevra-Therapeutics-Appoints-Biopharma-Veteran-Wendy-Dixon-Ph-D-to-Board-of-Directors.html", "time_published": "20230330T113000", "authors": ["Zevra Therapeutics"], "summary": "CELEBRATION, Fla., March 30, 2023 ( GLOBE NEWSWIRE ) -- Zevra Therapeutics ( NasdaqGS: ZVRA ) ( \"Zevra\" or the \"Company\" and formerly KemPharm, Inc. ) , a rare disease therapeutics company, today announced that it has appointed Wendy L. Dixon, Ph.D., to the Company's Board of Directors ( the ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/cf39ab90-8c07-407d-a7ea-b7c9d48d44c4", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.162252, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "WEN", "relevance_score": "0.033098", "ticker_sentiment_score": "0.152775", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ZVRA", "relevance_score": "0.131823", "ticker_sentiment_score": "0.091583", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.033098", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOVA", "relevance_score": "0.033098", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.033098", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VYGR", "relevance_score": "0.033098", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDTX", "relevance_score": "0.033098", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.033098", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALKS", "relevance_score": "0.033098", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.066139", "ticker_sentiment_score": "0.070237", "ticker_sentiment_label": "Neutral"}]}, {"title": "Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update", "url": "https://www.globenewswire.com/news-release/2023/03/09/2623950/0/en/Black-Diamond-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Provides-Corporate-Update.html", "time_published": "20230309T123000", "authors": ["Inc", "Black Diamond Therapeutics"], "summary": "CAMBRIDGE, Mass. and NEW YORK, March 09, 2023 ( GLOBE NEWSWIRE ) -- Black Diamond Therapeutics, Inc. ( Nasdaq: BDTX ) , a clinical-stage precision oncology medicine company developing MasterKey therapies designed to overcome limitations of existing therapies by targeting families of oncogenic ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/b8da4d92-789b-4f0a-a1e2-2739af370155?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.905476"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.045216, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.618054", "ticker_sentiment_score": "0.068149", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.396327", "ticker_sentiment_score": "0.079066", "ticker_sentiment_label": "Neutral"}]}, {"title": "Black Diamond Therapeutics Announces Changes to Board of Directors", "url": "https://www.globenewswire.com/news-release/2022/12/19/2576240/0/en/Black-Diamond-Therapeutics-Announces-Changes-to-Board-of-Directors.html", "time_published": "20221219T130000", "authors": ["Black Diamond Therapeutics", "Inc"], "summary": "CAMBRIDGE, Mass. and NEW YORK, Dec. 19, 2022 ( GLOBE NEWSWIRE ) -- Black Diamond Therapeutics, Inc. ( Nasdaq: BDTX ) , a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that Chairman of the Board of Directors, Robert ( Bob ) A.", "banner_image": "https://ml.globenewswire.com/Resource/Download/b8da4d92-789b-4f0a-a1e2-2739af370155?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.17043, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.28987", "ticker_sentiment_score": "0.110512", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.574235", "ticker_sentiment_score": "0.466587", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.042346", "ticker_sentiment_score": "-0.004888", "ticker_sentiment_label": "Neutral"}, {"ticker": "GTHX", "relevance_score": "0.126561", "ticker_sentiment_score": "-0.005848", "ticker_sentiment_label": "Neutral"}]}, {"title": "Black Diamond Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company - Black Diamond Therapeutic  ( NASDAQ:BDTX ) ", "url": "https://www.benzinga.com/pressreleases/22/12/g30039637/black-diamond-therapeutics-announces-spinout-of-launchpad-therapeutics-inc-an-antibody-focused-pre", "time_published": "20221212T130000", "authors": ["Globe Newswire"], "summary": "- $30M Series A investment from Versant Ventures and NEA- CAMBRIDGE, Mass. and NEW YORK, Dec. 12, 2022 ( GLOBE NEWSWIRE ) -- Black Diamond Therapeutics, Inc.", "banner_image": "", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.972756"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.122591, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.220236", "ticker_sentiment_score": "-0.001723", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.424012", "ticker_sentiment_score": "0.166701", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "$3 Million Bet On Taysha Gene Therapies? Check Out These 3 Penny Stocks Insiders Are Buying - Transact Technologies  ( NASDAQ:TACT ) , Black Diamond Therapeutic  ( NASDAQ:BDTX ) ", "url": "https://www.benzinga.com/trading-ideas/long-ideas/22/11/29550427/3-million-bet-on-taysha-gene-therapies-check-out-these-3-penny-stocks-insiders-are-buyin", "time_published": "20221103T154240", "authors": ["Lisa Levin"], "summary": "The Dow Jones closed lower by more than 500 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/11/03/image15.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.258084, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.524949", "ticker_sentiment_score": "0.312793", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TACT", "relevance_score": "0.432291", "ticker_sentiment_score": "0.386964", "ticker_sentiment_label": "Bullish"}, {"ticker": "BDIMF", "relevance_score": "0.432291", "ticker_sentiment_score": "0.27845", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSHA", "relevance_score": "0.524949", "ticker_sentiment_score": "0.41057", "ticker_sentiment_label": "Bullish"}]}, {"title": "Black Diamond Therapeutics And 2 Other Penny Stocks Insiders Are Aggressively Buying - Black Diamond Therapeutic  ( NASDAQ:BDTX ) , Applied Blockchain  ( NASDAQ:APLD ) ", "url": "https://www.benzinga.com/trading-ideas/long-ideas/22/11/29497847/black-diamond-therapeutics-and-2-other-penny-stocks-insiders-are-aggressively-buying", "time_published": "20221101T115233", "authors": ["Lisa Levin"], "summary": "The Dow Jones closed lower by more than 100 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/11/01/image_6.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Blockchain", "relevance_score": "0.682689"}], "overall_sentiment_score": 0.191277, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "APLD", "relevance_score": "0.533481", "ticker_sentiment_score": "0.252344", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BDTX", "relevance_score": "0.533481", "ticker_sentiment_score": "0.252344", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BSFC", "relevance_score": "0.533481", "ticker_sentiment_score": "0.210953", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BDIMF", "relevance_score": "0.439786", "ticker_sentiment_score": "0.224553", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SYY", "relevance_score": "0.115787", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:ETH", "relevance_score": "0.115787", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "4 Penny Stocks To Buy: Insider Picks For October", "url": "https://pennystocks.com/featured/2022/10/26/4-penny-stocks-to-buy-insider-picks-for-october/", "time_published": "20221026T142743", "authors": ["J. Samuel"], "summary": "Want to find penny stocks to buy? How about trying the \"Follow The Money\" trend? It's becoming more popular lately, especially in light of the recent stock market game being played. One day markets are up.", "banner_image": "https://pennystocks.com/wp-content/uploads/2022/08/penny-stocks-insider-trading-activity-this-week.jpg", "source": "PennyStocks.com", "category_within_source": "n/a", "source_domain": "pennystocks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Real Estate & Construction", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.222245, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.029581", "ticker_sentiment_score": "0.403062", "ticker_sentiment_label": "Bullish"}, {"ticker": "IMRA", "relevance_score": "0.147096", "ticker_sentiment_score": "0.130288", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.088581", "ticker_sentiment_score": "0.03639", "ticker_sentiment_label": "Neutral"}, {"ticker": "EBAY", "relevance_score": "0.029581", "ticker_sentiment_score": "0.114004", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDTX", "relevance_score": "0.204812", "ticker_sentiment_score": "0.05755", "ticker_sentiment_label": "Neutral"}, {"ticker": "COSM", "relevance_score": "0.059121", "ticker_sentiment_score": "0.003006", "ticker_sentiment_label": "Neutral"}, {"ticker": "LOCL", "relevance_score": "0.147096", "ticker_sentiment_score": "0.142039", "ticker_sentiment_label": "Neutral"}]}, {"title": "$1.8 Million Bet On MacroGenics? Check Out These 3 Penny Stocks Insiders Are Buying - Macrogenics  ( NASDAQ:MGNX ) , Black Diamond Therapeutic  ( NASDAQ:BDTX ) ", "url": "https://www.benzinga.com/trading-ideas/long-ideas/22/10/29386174/1-8-million-bet-on-macrogenics-check-out-these-3-penny-stocks-insiders-are-buying", "time_published": "20221024T195759", "authors": ["Lisa Levin"], "summary": "The Dow Jones traded higher by over 400 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/10/24/image_5.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.314056, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MGNX", "relevance_score": "0.540042", "ticker_sentiment_score": "0.295969", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BDTX", "relevance_score": "0.540042", "ticker_sentiment_score": "0.317671", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BDIMF", "relevance_score": "0.445569", "ticker_sentiment_score": "0.283865", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.117486", "ticker_sentiment_score": "0.214213", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why IMARA Shares Are Trading Higher By Over 13%; Here Are 22 Stocks Moving Premarket - Black Diamond Therapeutic  ( NASDAQ:BDTX ) , Avenue Therapeutics  ( NASDAQ:ATXI ) ", "url": "https://www.benzinga.com/news/22/10/29266749/why-imara-shares-are-trading-higher-by-over-13-here-are-22-stocks-moving-premarket", "time_published": "20221014T113437", "authors": ["Lisa Levin"], "summary": "Connexa Sports Technologies Inc. CNXA shares rose 80.1% to $0.4161 in pre-market trading after declining around 7% on Thursday. CONNEXA, last month, announced a $5.0 million private placement. Zovio Inc ZVO rose 16.8% to $0.1690 in pre-market trading. Eargo, Inc.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/10/14/image29.jpeg?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.050641, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVOS", "relevance_score": "0.143843", "ticker_sentiment_score": "-0.127594", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNXA", "relevance_score": "0.143843", "ticker_sentiment_score": "-0.036291", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZVO", "relevance_score": "0.143843", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NKLA", "relevance_score": "0.072217", "ticker_sentiment_score": "-0.036889", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDTX", "relevance_score": "0.143843", "ticker_sentiment_score": "-0.218535", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SGEN", "relevance_score": "0.072217", "ticker_sentiment_score": "0.064821", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSTV", "relevance_score": "0.143843", "ticker_sentiment_score": "-0.13756", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.072217", "ticker_sentiment_score": "-0.177443", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "FNHC", "relevance_score": "0.143843", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "QLGN", "relevance_score": "0.143843", "ticker_sentiment_score": "-0.338335", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "LOTZ", "relevance_score": "0.143843", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "OBLG", "relevance_score": "0.143843", "ticker_sentiment_score": "-0.05453", "ticker_sentiment_label": "Neutral"}, {"ticker": "QNGY", "relevance_score": "0.143843", "ticker_sentiment_score": "0.168716", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SHPH", "relevance_score": "0.143843", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NUTX", "relevance_score": "0.143843", "ticker_sentiment_score": "-0.168716", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "IMRA", "relevance_score": "0.214304", "ticker_sentiment_score": "0.27067", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NUWE", "relevance_score": "0.214304", "ticker_sentiment_score": "0.135414", "ticker_sentiment_label": "Neutral"}, {"ticker": "SXTC", "relevance_score": "0.214304", "ticker_sentiment_score": "0.278443", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MAPS", "relevance_score": "0.143843", "ticker_sentiment_score": "0.243391", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RMO", "relevance_score": "0.214304", "ticker_sentiment_score": "-0.062778", "ticker_sentiment_label": "Neutral"}, {"ticker": "EAR", "relevance_score": "0.214304", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZLAB", "relevance_score": "0.214304", "ticker_sentiment_score": "0.107506", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATXI", "relevance_score": "0.143843", "ticker_sentiment_score": "-0.05453", "ticker_sentiment_label": "Neutral"}, {"ticker": "GEHI", "relevance_score": "0.143843", "ticker_sentiment_score": "-0.05453", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBGI", "relevance_score": "0.143843", "ticker_sentiment_score": "0.213558", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Pyxis Oncology Reports Financial Results for the Second Quarter Ended June 30, 2022 and Provides Pipeline Update", "url": "https://www.globenewswire.com/news-release/2022/08/15/2498065/0/en/Pyxis-Oncology-Reports-Financial-Results-for-the-Second-Quarter-Ended-June-30-2022-and-Provides-Pipeline-Update.html", "time_published": "20220815T110000", "authors": ["Pyxis Oncology"], "summary": "\u2022 Prioritized pipeline to focus on most advanced programs while maintaining financial flexibility to pursue business development opportunities ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/dc89ff40-4e91-444f-9ffd-3d68093dc029?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.137052, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "IREHF", "relevance_score": "0.024597", "ticker_sentiment_score": "0.003808", "ticker_sentiment_label": "Neutral"}, {"ticker": "PYXS", "relevance_score": "0.356268", "ticker_sentiment_score": "0.193997", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BDIMF", "relevance_score": "0.024597", "ticker_sentiment_score": "-0.011764", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTMX", "relevance_score": "0.024597", "ticker_sentiment_score": "-0.011764", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDTX", "relevance_score": "0.024597", "ticker_sentiment_score": "-0.011764", "ticker_sentiment_label": "Neutral"}, {"ticker": "XLO", "relevance_score": "0.024597", "ticker_sentiment_score": "-0.011764", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.024597", "ticker_sentiment_score": "-0.011764", "ticker_sentiment_label": "Neutral"}]}, {"title": "Black Diamond Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update", "url": "https://www.globenewswire.com/news-release/2022/08/09/2494791/0/en/Black-Diamond-Therapeutics-Reports-Second-Quarter-2022-Financial-Results-and-Provides-Corporate-Update.html", "time_published": "20220809T120000", "authors": ["Inc", "Black Diamond Therapeutics"], "summary": "CAMBRIDGE, Mass. and NEW YORK, Aug. 09, 2022 ( GLOBE NEWSWIRE ) -- Black Diamond Therapeutics, Inc. ( Nasdaq: BDTX ) , a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today reported financial results for the second quarter ended June 30, ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/b8da4d92-789b-4f0a-a1e2-2739af370155?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.026369, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.506284", "ticker_sentiment_score": "0.019398", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.457055", "ticker_sentiment_score": "0.0182", "ticker_sentiment_label": "Neutral"}, {"ticker": "NUVB", "relevance_score": "0.030331", "ticker_sentiment_score": "0.003814", "ticker_sentiment_label": "Neutral"}]}, {"title": "Black Diamond Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Virtual Conference", "url": "https://www.globenewswire.com/news-release/2022/08/03/2491321/0/en/Black-Diamond-Therapeutics-to-Present-at-the-2022-Wedbush-PacGrow-Healthcare-Virtual-Conference.html", "time_published": "20220803T120000", "authors": ["Inc", "Black Diamond Therapeutics"], "summary": "CAMBRIDGE, Mass. and NEW YORK, Aug. 03, 2022 ( GLOBE NEWSWIRE ) -- Black Diamond Therapeutics, Inc. ( Nasdaq: BDTX ) , a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that its President and Chief Executive Officer, David M.", "banner_image": "https://ml.globenewswire.com/Resource/Download/b8da4d92-789b-4f0a-a1e2-2739af370155?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.019217, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.412298", "ticker_sentiment_score": "0.002849", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.79415", "ticker_sentiment_score": "0.004061", "ticker_sentiment_label": "Neutral"}]}, {"title": "$1 Million Bet On CalAmp? 4 Penny Stocks Insiders are Buying", "url": "https://www.benzinga.com/trading-ideas/long-ideas/22/07/27931578/1-million-bet-on-calamp-4-penny-stocks-insiders-are-buying", "time_published": "20220701T133116", "authors": ["Lisa Levin"], "summary": "U.S. stocks opened slightly lower on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/07/01/image20.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.214378"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": -0.058991, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.453582", "ticker_sentiment_score": "0.062229", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.370556", "ticker_sentiment_score": "0.062229", "ticker_sentiment_label": "Neutral"}, {"ticker": "HRTG", "relevance_score": "0.453582", "ticker_sentiment_score": "-0.046628", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAMP", "relevance_score": "0.453582", "ticker_sentiment_score": "-0.251486", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.096014", "ticker_sentiment_score": "0.015282", "ticker_sentiment_label": "Neutral"}]}, {"title": "Iovance Biotherapeutics Appoints Wendy L. Dixon, Ph.D., to Board of Directors", "url": "https://www.globenewswire.com/news-release/2022/06/13/2461601/0/en/Iovance-Biotherapeutics-Appoints-Wendy-L-Dixon-Ph-D-to-Board-of-Directors.html", "time_published": "20220613T200100", "authors": ["Iovance Biotherapeutics Inc"], "summary": "SAN CARLOS, Calif., June 13, 2022 ( GLOBE NEWSWIRE ) -- Iovance Biotherapeutics, Inc. ( NASDAQ: IOVA ) , a late-stage biotechnology company developing novel T cell-based cancer immunotherapies ( tumor infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL ) , today announced the ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/d0986bd6-4603-4e31-8ed1-f23b3e123605?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.034533, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDIMF", "relevance_score": "0.029501", "ticker_sentiment_score": "0.008901", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOVA", "relevance_score": "0.117601", "ticker_sentiment_score": "0.039235", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.029501", "ticker_sentiment_score": "0.008901", "ticker_sentiment_label": "Neutral"}, {"ticker": "VYGR", "relevance_score": "0.029501", "ticker_sentiment_score": "0.008901", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARVN", "relevance_score": "0.029501", "ticker_sentiment_score": "0.008901", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDTX", "relevance_score": "0.029501", "ticker_sentiment_score": "0.008901", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.029501", "ticker_sentiment_score": "0.008901", "ticker_sentiment_label": "Neutral"}, {"ticker": "SESN", "relevance_score": "0.029501", "ticker_sentiment_score": "0.008901", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALKS", "relevance_score": "0.029501", "ticker_sentiment_score": "0.008901", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.029501", "ticker_sentiment_score": "0.032284", "ticker_sentiment_label": "Neutral"}]}, {"title": "Iovance Biotherapeutics Appoints Wendy L. Dixon, Ph.D., to Board of Directors", "url": "https://www.benzinga.com/pressreleases/22/06/g27684549/iovance-biotherapeutics-appoints-wendy-l-dixon-ph-d-to-board-of-directors", "time_published": "20220613T200100", "authors": ["Globe Newswire"], "summary": "SAN CARLOS, Calif., June 13, 2022 ( GLOBE NEWSWIRE ) -- Iovance Biotherapeutics, Inc. IOVA, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies ( tumor infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL ) , today announced the appointment of ...", "banner_image": "", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.029038, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDIMF", "relevance_score": "0.028285", "ticker_sentiment_score": "0.007947", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOVA", "relevance_score": "0.140715", "ticker_sentiment_score": "0.037683", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.028285", "ticker_sentiment_score": "0.007947", "ticker_sentiment_label": "Neutral"}, {"ticker": "VYGR", "relevance_score": "0.028285", "ticker_sentiment_score": "0.007947", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARVN", "relevance_score": "0.028285", "ticker_sentiment_score": "0.007947", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDTX", "relevance_score": "0.028285", "ticker_sentiment_score": "0.007947", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.028285", "ticker_sentiment_score": "0.007947", "ticker_sentiment_label": "Neutral"}, {"ticker": "SESN", "relevance_score": "0.028285", "ticker_sentiment_score": "0.007947", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALKS", "relevance_score": "0.028285", "ticker_sentiment_score": "0.007947", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.028285", "ticker_sentiment_score": "0.032969", "ticker_sentiment_label": "Neutral"}]}, {"title": "Black Diamond Therapeutics Appoints Sergey Yurasov, M.D., Ph.D., as Chief Medical Officer", "url": "https://www.globenewswire.com/news-release/2022/06/01/2454051/0/en/Black-Diamond-Therapeutics-Appoints-Sergey-Yurasov-M-D-Ph-D-as-Chief-Medical-Officer.html", "time_published": "20220601T110000", "authors": ["Black Diamond Therapeutics", "Inc"], "summary": "- Dr. Yurasov brings over 25 years of experience in oncology drug development and regulatory expertise -", "banner_image": "https://ml.globenewswire.com/Resource/Download/b8da4d92-789b-4f0a-a1e2-2739af370155?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.24014, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.297621", "ticker_sentiment_score": "0.143337", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLVS", "relevance_score": "0.033865", "ticker_sentiment_score": "0.02085", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.41901", "ticker_sentiment_score": "0.31681", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NUVB", "relevance_score": "0.101353", "ticker_sentiment_score": "0.02085", "ticker_sentiment_label": "Neutral"}]}, {"title": "Black Diamond Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update", "url": "https://www.globenewswire.com/news-release/2022/05/11/2441307/0/en/Black-Diamond-Therapeutics-Reports-First-Quarter-2022-Financial-Results-and-Provides-Corporate-Update.html", "time_published": "20220511T203000", "authors": ["Black Diamond Therapeutics", "Inc"], "summary": "CAMBRIDGE, Mass. and NEW YORK, May 11, 2022 ( GLOBE NEWSWIRE ) -- Black Diamond Therapeutics, Inc. ( Nasdaq: BDTX ) , a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today reported financial results for the first quarter ended March 31, 202", "banner_image": "https://ml.globenewswire.com/Resource/Download/b8da4d92-789b-4f0a-a1e2-2739af370155?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}], "overall_sentiment_score": 0.055137, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.538939", "ticker_sentiment_score": "0.055546", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.408092", "ticker_sentiment_score": "0.091291", "ticker_sentiment_label": "Neutral"}]}, {"title": "Executives Buy Around $1.6M Of 4 Penny Stocks", "url": "https://www.benzinga.com/trading-ideas/long-ideas/22/05/26930968/executives-buy-around-1-6m-of-4-penny-stocks", "time_published": "20220502T131054", "authors": ["Lisa Levin"], "summary": "US crude oil futures traded lower on Monday. Investors, meanwhile, focused on some notable insider trades.\nWhen insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in th", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/05/02/image_4.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.214378"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": -0.005356, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.377712", "ticker_sentiment_score": "0.032597", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.306484", "ticker_sentiment_score": "0.032597", "ticker_sentiment_label": "Neutral"}, {"ticker": "HMTV", "relevance_score": "0.377712", "ticker_sentiment_score": "0.002004", "ticker_sentiment_label": "Neutral"}, {"ticker": "NNUP", "relevance_score": "0.306484", "ticker_sentiment_score": "0.003087", "ticker_sentiment_label": "Neutral"}]}, {"title": "Black Diamond Cuts 30% Of Its Workforce, Discontinues Drug From its 'MasterKey' Pipeline", "url": "https://www.benzinga.com/general/biotech/22/04/26792853/black-diamond-cuts-30-of-its-workforce-discontinues-drug-from-its-masterkey-chest", "time_published": "20220425T174347", "authors": ["Vandana Singh"], "summary": "Black Diamond Therapeutics Inc  ( NASDAQ: BDTX )  is realigning its resources to extend its cash runway into the third quarter of 2024.\nThe Company has discontinued the development of BDTX-189, an orally available small-molecule inhibitor that targets mutations of EGFR and HER2 kinases.\nBlack Diamon", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/04/25/aapharma_13.png?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.078447, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.960704", "ticker_sentiment_score": "0.019575", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.353059", "ticker_sentiment_score": "-0.200824", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Executives Buy Around $5M Of 3 Penny Stocks", "url": "https://www.benzinga.com/trading-ideas/long-ideas/22/04/26734951/executives-buy-around-5m-of-3-penny-stocks", "time_published": "20220421T122844", "authors": ["Lisa Levin"], "summary": "US stocks closed mixed on Wednesday. Investors, meanwhile, focused on some notable insider trades.\nWhen insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their over", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/04/21/image_1.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.161647"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": -0.003582, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.571178", "ticker_sentiment_score": "0.027673", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.402135", "ticker_sentiment_score": "0.027673", "ticker_sentiment_label": "Neutral"}, {"ticker": "INZY", "relevance_score": "0.402135", "ticker_sentiment_score": "0.015424", "ticker_sentiment_label": "Neutral"}, {"ticker": "SCTL", "relevance_score": "0.307603", "ticker_sentiment_score": "0.000648", "ticker_sentiment_label": "Neutral"}]}, {"title": "4 Stocks Under $5 Insiders Are Aggressively Buying", "url": "https://www.benzinga.com/trading-ideas/long-ideas/22/04/26663091/4-stocks-under-5-insiders-are-aggressively-buying", "time_published": "20220418T124828", "authors": ["Lisa Levin"], "summary": "US crude oil futures traded lower on Monday. Investors, meanwhile, focused on some notable insider trades.\nWhen insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in th", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/04/18/image_2.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.214378"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": -0.009244, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.361407", "ticker_sentiment_score": "0.040191", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.361407", "ticker_sentiment_score": "0.006476", "ticker_sentiment_label": "Neutral"}, {"ticker": "RWLK", "relevance_score": "0.442853", "ticker_sentiment_score": "0.005745", "ticker_sentiment_label": "Neutral"}, {"ticker": "OCX", "relevance_score": "0.442853", "ticker_sentiment_score": "0.007484", "ticker_sentiment_label": "Neutral"}, {"ticker": "HMTV", "relevance_score": "0.442853", "ticker_sentiment_score": "0.002413", "ticker_sentiment_label": "Neutral"}]}, {"title": "Black Diamond Therapeutics Announces First Patient Dosed in Phase 1 Study of BDTX-1535, a MasterKey Inhibitor of EGFR for the Treatment of Glioblastoma and Non-Small Cell Lung Cancer", "url": "https://www.globenewswire.com/news-release/2022/04/18/2423594/0/en/Black-Diamond-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Study-of-BDTX-1535-a-MasterKey-Inhibitor-of-EGFR-for-the-Treatment-of-Glioblastoma-and-Non-Small-Cell-Lung-Cance.html", "time_published": "20220418T110000", "authors": ["Black Diamond Therapeutics", "Inc"], "summary": "- Clinical update expected in second half of 2023 -", "banner_image": "https://ml.globenewswire.com/Resource/Download/b8da4d92-789b-4f0a-a1e2-2739af370155?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.161647"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.076017, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.350316", "ticker_sentiment_score": "0.086951", "ticker_sentiment_label": "Neutral"}, {"ticker": "BTTX", "relevance_score": "0.036228", "ticker_sentiment_score": "0.016384", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.350316", "ticker_sentiment_score": "0.114926", "ticker_sentiment_label": "Neutral"}]}, {"title": "53 Biggest Movers From Yesterday", "url": "https://www.benzinga.com/news/22/04/26539460/53-biggest-movers-from-yesterday", "time_published": "20220408T084938", "authors": [], "summary": "Gainers\nMedAvail Holdings, Inc.  ( NASDAQ: MDVL )  shares surged 64.4% to close at $1.41 on Thursday. Ally Bridge Group reported a purchase of 21.176 million shares of MedAvail Holdings for an average price of $1.06 per share.\nTrevi Therapeutics, Inc.  ( NASDAQ: TRVI )  gained 56.8% to close at $2.9", "banner_image": "https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/04/07/yesterdays_movers_0.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.928769"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": -0.029366, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CUEN", "relevance_score": "0.063763", "ticker_sentiment_score": "1.3e-05", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBBY", "relevance_score": "0.063763", "ticker_sentiment_score": "-0.105335", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADN", "relevance_score": "0.095517", "ticker_sentiment_score": "0.018573", "ticker_sentiment_label": "Neutral"}, {"ticker": "BTBD", "relevance_score": "0.063763", "ticker_sentiment_score": "0.007445", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDK", "relevance_score": "0.063763", "ticker_sentiment_score": "0.004727", "ticker_sentiment_label": "Neutral"}, {"ticker": "IRNT", "relevance_score": "0.063763", "ticker_sentiment_score": "-0.590524", "ticker_sentiment_label": "Bearish"}, {"ticker": "PHAS", "relevance_score": "0.063763", "ticker_sentiment_score": "0.004923", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.031907", "ticker_sentiment_score": "0.018716", "ticker_sentiment_label": "Neutral"}, {"ticker": "JAZZ", "relevance_score": "0.031907", "ticker_sentiment_score": "0.009724", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRVI", "relevance_score": "0.063763", "ticker_sentiment_score": "0.005283", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLSN", "relevance_score": "0.095517", "ticker_sentiment_score": "0.003145", "ticker_sentiment_label": "Neutral"}, {"ticker": "AUR", "relevance_score": "0.063763", "ticker_sentiment_score": "0.000794", "ticker_sentiment_label": "Neutral"}, {"ticker": "VERY", "relevance_score": "0.031907", "ticker_sentiment_score": "0.01332", "ticker_sentiment_label": "Neutral"}, {"ticker": "BWV", "relevance_score": "0.063763", "ticker_sentiment_score": "0.002047", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNDT", "relevance_score": "0.063763", "ticker_sentiment_score": "0.000351", "ticker_sentiment_label": "Neutral"}, {"ticker": "AEI", "relevance_score": "0.063763", "ticker_sentiment_score": "0.001714", "ticker_sentiment_label": "Neutral"}, {"ticker": "IQ", "relevance_score": "0.063763", "ticker_sentiment_score": "-0.014576", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDVL", "relevance_score": "0.095517", "ticker_sentiment_score": "0.001614", "ticker_sentiment_label": "Neutral"}, {"ticker": "MOXC", "relevance_score": "0.063763", "ticker_sentiment_score": "0.00218", "ticker_sentiment_label": "Neutral"}, {"ticker": "FEDU", "relevance_score": "0.063763", "ticker_sentiment_score": "0.000403", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAN", "relevance_score": "0.031907", "ticker_sentiment_score": "-0.067735", "ticker_sentiment_label": "Neutral"}, {"ticker": "AEHL", "relevance_score": "0.063763", "ticker_sentiment_score": "0.000326", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMTE", "relevance_score": "0.063763", "ticker_sentiment_score": "0.001222", "ticker_sentiment_label": "Neutral"}, {"ticker": "NRSN", "relevance_score": "0.095517", "ticker_sentiment_score": "-0.000404", "ticker_sentiment_label": "Neutral"}, {"ticker": "HOWL", "relevance_score": "0.063763", "ticker_sentiment_score": "0.009724", "ticker_sentiment_label": "Neutral"}, {"ticker": "FCUV", "relevance_score": "0.063763", "ticker_sentiment_score": "0.003854", "ticker_sentiment_label": "Neutral"}, {"ticker": "TANH", "relevance_score": "0.063763", "ticker_sentiment_score": "0.00055", "ticker_sentiment_label": "Neutral"}, {"ticker": "VAPO", "relevance_score": "0.063763", "ticker_sentiment_score": "-0.002192", "ticker_sentiment_label": "Neutral"}, {"ticker": "MNTS", "relevance_score": "0.063763", "ticker_sentiment_score": "0.018716", "ticker_sentiment_label": "Neutral"}, {"ticker": "HPQ", "relevance_score": "0.063763", "ticker_sentiment_score": "0.000635", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVDA", "relevance_score": "0.063763", "ticker_sentiment_score": "0.000625", "ticker_sentiment_label": "Neutral"}, {"ticker": "EURN", "relevance_score": "0.063763", "ticker_sentiment_score": "0.003507", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCCS", "relevance_score": "0.063763", "ticker_sentiment_score": "-0.001166", "ticker_sentiment_label": "Neutral"}, {"ticker": "VNET", "relevance_score": "0.063763", "ticker_sentiment_score": "-0.009064", "ticker_sentiment_label": "Neutral"}, {"ticker": "BPTS", "relevance_score": "0.063763", "ticker_sentiment_score": "0.001865", "ticker_sentiment_label": "Neutral"}, {"ticker": "HTGM", "relevance_score": "0.063763", "ticker_sentiment_score": "0.041079", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEED", "relevance_score": "0.063763", "ticker_sentiment_score": "0.008737", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDTX", "relevance_score": "0.063763", "ticker_sentiment_score": "0.003341", "ticker_sentiment_label": "Neutral"}, {"ticker": "HTCR", "relevance_score": "0.063763", "ticker_sentiment_score": "0.002788", "ticker_sentiment_label": "Neutral"}, {"ticker": "MACK", "relevance_score": "0.063763", "ticker_sentiment_score": "0.004581", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.031907", "ticker_sentiment_score": "0.003341", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLSE", "relevance_score": "0.095517", "ticker_sentiment_score": "-0.199841", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "INKT", "relevance_score": "0.063763", "ticker_sentiment_score": "0.002858", "ticker_sentiment_label": "Neutral"}, {"ticker": "APTX", "relevance_score": "0.063763", "ticker_sentiment_score": "-0.390132", "ticker_sentiment_label": "Bearish"}, {"ticker": "GWGH", "relevance_score": "0.063763", "ticker_sentiment_score": "0.001598", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBFM", "relevance_score": "0.095517", "ticker_sentiment_score": "0.087491", "ticker_sentiment_label": "Neutral"}, {"ticker": "RAD", "relevance_score": "0.063763", "ticker_sentiment_score": "-0.001649", "ticker_sentiment_label": "Neutral"}, {"ticker": "SST", "relevance_score": "0.063763", "ticker_sentiment_score": "0.009975", "ticker_sentiment_label": "Neutral"}, {"ticker": "STRC", "relevance_score": "0.063763", "ticker_sentiment_score": "0.002651", "ticker_sentiment_label": "Neutral"}, {"ticker": "HYMLF", "relevance_score": "0.031907", "ticker_sentiment_score": "0.018573", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBAI", "relevance_score": "0.063763", "ticker_sentiment_score": "0.00139", "ticker_sentiment_label": "Neutral"}, {"ticker": "IKNA", "relevance_score": "0.063763", "ticker_sentiment_score": "0.002861", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEO", "relevance_score": "0.063763", "ticker_sentiment_score": "0.003003", "ticker_sentiment_label": "Neutral"}, {"ticker": "APCX", "relevance_score": "0.063763", "ticker_sentiment_score": "0.002261", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.031907", "ticker_sentiment_score": "-0.067735", "ticker_sentiment_label": "Neutral"}]}, {"title": "Black Diamond Therapeutics to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference", "url": "https://www.globenewswire.com/news-release/2022/04/07/2418915/0/en/Black-Diamond-Therapeutics-to-Present-at-the-Canaccord-Genuity-Horizons-in-Oncology-Virtual-Conference.html", "time_published": "20220407T203000", "authors": ["Black Diamond Therapeutics", "Inc"], "summary": "CAMBRIDGE, Mass. and NEW YORK, April  07, 2022   ( GLOBE NEWSWIRE )  -- Black Diamond Therapeutics, Inc.  ( Nasdaq: BDTX ) , a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that its President and Chief Executive Officer, David M.", "banner_image": "https://ml.globenewswire.com/Resource/Download/b8da4d92-789b-4f0a-a1e2-2739af370155?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.105789, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CCORF", "relevance_score": "0.140403", "ticker_sentiment_score": "0.010469", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDTX", "relevance_score": "0.404346", "ticker_sentiment_score": "0.105789", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.784361", "ticker_sentiment_score": "0.105789", "ticker_sentiment_label": "Neutral"}]}, {"title": "38 Stocks Moving In Thursday's Mid-Day Session", "url": "https://www.benzinga.com/news/22/04/26529716/38-stocks-moving-in-thursdays-mid-day-session", "time_published": "20220407T171413", "authors": [], "summary": "Gainers\nMedAvail Holdings, Inc.  ( NASDAQ: MDVL )  jumped 57.6% to $1.3515. Ally Bridge Group reported a purchase of 21.176 million shares of MedAvail Holdings for an average price of $1.06 per share.\nMomentus Inc.   ( NASDAQ: MNTS )  shares jumped 48.4% to $4.3786 as the company signed multiple lau", "banner_image": "https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/04/07/mid-day_movers_image.jpg", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.928769"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": -0.051012, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VAPO", "relevance_score": "0.087969", "ticker_sentiment_score": "-0.004094", "ticker_sentiment_label": "Neutral"}, {"ticker": "MNTS", "relevance_score": "0.087969", "ticker_sentiment_score": "0.010444", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBBY", "relevance_score": "0.087969", "ticker_sentiment_score": "-0.250558", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "HPQ", "relevance_score": "0.087969", "ticker_sentiment_score": "0.000287", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVDA", "relevance_score": "0.087969", "ticker_sentiment_score": "1.8e-05", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADN", "relevance_score": "0.131619", "ticker_sentiment_score": "0.012162", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDK", "relevance_score": "0.087969", "ticker_sentiment_score": "0.004531", "ticker_sentiment_label": "Neutral"}, {"ticker": "EURN", "relevance_score": "0.087969", "ticker_sentiment_score": "0.001009", "ticker_sentiment_label": "Neutral"}, {"ticker": "IRNT", "relevance_score": "0.087969", "ticker_sentiment_score": "-0.488893", "ticker_sentiment_label": "Bearish"}, {"ticker": "CCCS", "relevance_score": "0.087969", "ticker_sentiment_score": "-0.002273", "ticker_sentiment_label": "Neutral"}, {"ticker": "VNET", "relevance_score": "0.087969", "ticker_sentiment_score": "-0.056262", "ticker_sentiment_label": "Neutral"}, {"ticker": "BPTS", "relevance_score": "0.087969", "ticker_sentiment_score": "-0.000803", "ticker_sentiment_label": "Neutral"}, {"ticker": "HTGM", "relevance_score": "0.087969", "ticker_sentiment_score": "0.052563", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.044051", "ticker_sentiment_score": "0.010444", "ticker_sentiment_label": "Neutral"}, {"ticker": "JAZZ", "relevance_score": "0.044051", "ticker_sentiment_score": "0.005025", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEED", "relevance_score": "0.087969", "ticker_sentiment_score": "0.004258", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDTX", "relevance_score": "0.087969", "ticker_sentiment_score": "0.001125", "ticker_sentiment_label": "Neutral"}, {"ticker": "AUR", "relevance_score": "0.087969", "ticker_sentiment_score": "0.000273", "ticker_sentiment_label": "Neutral"}, {"ticker": "MACK", "relevance_score": "0.087969", "ticker_sentiment_score": "0.000594", "ticker_sentiment_label": "Neutral"}, {"ticker": "BWV", "relevance_score": "0.087969", "ticker_sentiment_score": "4.3e-05", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.044051", "ticker_sentiment_score": "0.001125", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNDT", "relevance_score": "0.087969", "ticker_sentiment_score": "-0.001205", "ticker_sentiment_label": "Neutral"}, {"ticker": "IQ", "relevance_score": "0.087969", "ticker_sentiment_score": "-0.01436", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDVL", "relevance_score": "0.131619", "ticker_sentiment_score": "0.000711", "ticker_sentiment_label": "Neutral"}, {"ticker": "MOXC", "relevance_score": "0.087969", "ticker_sentiment_score": "0.000425", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLSE", "relevance_score": "0.131619", "ticker_sentiment_score": "-0.230851", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "INKT", "relevance_score": "0.087969", "ticker_sentiment_score": "0.000873", "ticker_sentiment_label": "Neutral"}, {"ticker": "APTX", "relevance_score": "0.087969", "ticker_sentiment_score": "-0.401341", "ticker_sentiment_label": "Bearish"}, {"ticker": "GWGH", "relevance_score": "0.087969", "ticker_sentiment_score": "0.000477", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBFM", "relevance_score": "0.131619", "ticker_sentiment_score": "0.090423", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAN", "relevance_score": "0.044051", "ticker_sentiment_score": "-0.033101", "ticker_sentiment_label": "Neutral"}, {"ticker": "RAD", "relevance_score": "0.087969", "ticker_sentiment_score": "-0.009757", "ticker_sentiment_label": "Neutral"}, {"ticker": "SST", "relevance_score": "0.087969", "ticker_sentiment_score": "0.007895", "ticker_sentiment_label": "Neutral"}, {"ticker": "HYMLF", "relevance_score": "0.044051", "ticker_sentiment_score": "0.012162", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBAI", "relevance_score": "0.087969", "ticker_sentiment_score": "0.000845", "ticker_sentiment_label": "Neutral"}, {"ticker": "IKNA", "relevance_score": "0.087969", "ticker_sentiment_score": "0.000434", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMTE", "relevance_score": "0.087969", "ticker_sentiment_score": "0.000412", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEO", "relevance_score": "0.087969", "ticker_sentiment_score": "0.000757", "ticker_sentiment_label": "Neutral"}, {"ticker": "HOWL", "relevance_score": "0.087969", "ticker_sentiment_score": "0.005025", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.044051", "ticker_sentiment_score": "-0.033101", "ticker_sentiment_label": "Neutral"}]}, {"title": "Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update", "url": "https://www.globenewswire.com/news-release/2022/03/17/2405694/0/en/Black-Diamond-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-Results-and-Provides-Corporate-Update.html", "time_published": "20220317T210000", "authors": ["Inc", "Black Diamond Therapeutics"], "summary": "CAMBRIDGE, Mass. and NEW YORK, March  17, 2022   ( GLOBE NEWSWIRE )  -- Black Diamond Therapeutics, Inc.  ( Nasdaq: BDTX ) , a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today reported financial results for the fourth quarter and full year en", "banner_image": "https://ml.globenewswire.com/Resource/Download/b8da4d92-789b-4f0a-a1e2-2739af370155?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.140087, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.458031", "ticker_sentiment_score": "0.140087", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.510529", "ticker_sentiment_score": "0.152364", "ticker_sentiment_label": "Somewhat-Bullish"}]}]}